Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06413355 · ClinicalTrials.gov registry record · Phase 1
FAPI-74 PET/CT in Adults With Fibrosis
A Phase 1 study of Fibrosis (Morphologic Abnormality), sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06413355 is a Phase 1 study of Fibrosis (Morphologic Abnormality) that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06413355, a Phase 1 study of Fibrosis (Morphologic Abnormality), is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol is intended as a basket protocol designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging the presence of fibrosis caused by a variety of medical conditions where fibrosis is believed to lead to pathological effects and poor prognosis.
Conditions Studied
Interventions
- DRUG [F-18]-FAPI-74
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-07-16 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06413355
The ClinicalTrials.gov registry entry for NCT06413355 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrosis (Morphologic Abnormality) appearing as the primary indexed condition, and to 1 intervention - of which [F-18]-FAPI-74 is the first listed.
NCT06413355 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06413355 about?
NCT06413355 is a clinical study titled "FAPI-74 PET/CT in Adults With Fibrosis". This protocol is intended as a basket protocol designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging the presence of fibrosis caused by a variety of medical conditions where fibrosis is believed to lead to pathological effects and poor prognosis.
What is the current status of trial NCT06413355?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2024-07-16. Estimated completion is 2027-07-30.
What conditions does trial NCT06413355 study?
This clinical trial studies the following conditions: Fibrosis (Morphologic Abnormality).
What interventions are being tested in trial NCT06413355?
The interventions under investigation include: [F-18]-FAPI-74 (DRUG).
Who is sponsoring clinical trial NCT06413355?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06413355 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.